128 related articles for article (PubMed ID: 7499447)
21. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
22. Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine.
Papadopoulos I; Rudolph P; Weichert-Jacobsen K; Thiemann O; Papadopoulou D
Urology; 1996 Sep; 48(3):373-8. PubMed ID: 8804488
[TBL] [Abstract][Full Text] [Related]
23. Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanoma.
Thomas H; Barton C; Saini A; Dalgleish A; Waxman J
Eur J Cancer; 1992; 28A(6-7):1047-9. PubMed ID: 1627371
[TBL] [Abstract][Full Text] [Related]
24. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
25. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
Figlin RA; Pierce WC; Belldegrun A
Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
[No Abstract] [Full Text] [Related]
26. Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Ku JH
Tumori; 2007; 93(1):68-74. PubMed ID: 17455874
[TBL] [Abstract][Full Text] [Related]
27. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
28. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
[TBL] [Abstract][Full Text] [Related]
30. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
31. Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2.
Atzpodien J; Reitz M
Cancer Biother Radiopharm; 2005 Aug; 20(4):410-6. PubMed ID: 16114989
[TBL] [Abstract][Full Text] [Related]
32. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.
Négrier S; Escudier B; Gomez F; Douillard JY; Ravaud A; Chevreau C; Buclon M; Pérol D; Lasset C
Ann Oncol; 2002 Sep; 13(9):1460-8. PubMed ID: 12196373
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation.
Joffe JK; Banks RE; Forbes MA; Hallam S; Jenkins A; Patel PM; Hall GD; Velikova G; Adams J; Crossley A; Johnson PW; Whicher JT; Selby PJ
Br J Urol; 1996 May; 77(5):638-49. PubMed ID: 8689103
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
Clark JI; Mehrabi J; Sosman JA; Logan TF; Margolin KA; Dutcher JP; Urba WJ; Ernstoff MS; McDermott DF; Lau AM; Atkins MB
J Immunother; 2007; 30(8):839-46. PubMed ID: 18049336
[TBL] [Abstract][Full Text] [Related]
36. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
Jeon SH; Chang SG; Kim JI
Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
[TBL] [Abstract][Full Text] [Related]
37. Predicting survival of patients with metastatic renal cell carcinoma.
Motzer RJ; Mazumdar M
Urologe A; 2004 Sep; 43 Suppl 3():S135-6. PubMed ID: 15148574
[TBL] [Abstract][Full Text] [Related]
38. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.
Palmer PA; Vinke J; Philip T; Negrier S; Atzpodien J; Kirchner H; Oskam R; Franks CR
Ann Oncol; 1992 Jun; 3(6):475-80. PubMed ID: 1498066
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors of immunotherapy in metastatic renal cell carcinoma.
Padrik P
Med Oncol; 2003; 20(4):325-34. PubMed ID: 14716028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
